Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Sara Baglivo"'
Autor:
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 163-171 (2023)
Abstract In this work, we report on a clinically significant response of meningeal carcinomatosis to repotrectinib in a woman with a heavily pretreated ROS1-rearranged non-small cell lung cancer (NSCLC) that harbored the concomitant solvent front G20
Externí odkaz:
https://doaj.org/article/3a4ed1b09b5d4c588436e9abe5843e1f
Autor:
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 173-174 (2024)
Externí odkaz:
https://doaj.org/article/721958e30de148fbbf729425efe8aa14
Autor:
Matteo Canale, Elisabetta Petracci, Paola Cravero, Marita Mariotti, Gabriele Minuti, Giulio Metro, Vienna Ludovini, Sara Baglivo, Maurizio Puccetti, Alessandra Dubini, Giovanni Martinelli, Angelo Delmonte, Lucio Crinò, Paola Ulivi
Publikováno v:
Translational Oncology, Vol 23, Iss , Pp 101471- (2022)
Non-small-cell lung cancer (NSCLC) is the primary cause of cancer-related death. Gene rearrangements involving the anaplastic lymphoma kinase (ALK) tyrosine kinase identify a clinical and molecular subset of NSCLC patients, who benefit from the monot
Externí odkaz:
https://doaj.org/article/9fcffe32bbf24565b0725968e3ffe4ea
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 341-350 (2020)
Abstract Oncogene-addicted non-small cell lung cancer (NSCLC) comprises a number of distinct disease subtypes, each of which is characterised by druggable genetic alterations. Among them, the receptor tyrosine kinase protein human epidermal receptor
Externí odkaz:
https://doaj.org/article/95a6b73ec2c3469890dcc2c163bee1e2
Autor:
Sara Baglivo, Vienna Ludovini, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila, Giulio Metro
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 333-339 (2020)
Abstract Patients with epidermal growth factor receptor and anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC) generally respond poorly to treatment with immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or
Externí odkaz:
https://doaj.org/article/f2f94527ae4c4133915f96ff3e4827bb
Autor:
Martina Mandarano, Elena Orecchini, Guido Bellezza, Jacopo Vannucci, Vienna Ludovini, Sara Baglivo, Francesca Romana Tofanetti, Rita Chiari, Elisabetta Loreti, Francesco Puma, Angelo Sidoni, Maria Laura Belladonna
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 9, p 4403 (2021)
The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) degrade tryptophan (Trp) into kynurenine (Kyn) at the initial step of an enzymatic pathway affecting T cell proliferation. IDO1 is highly expressed in various cancer types and associated with poor progn
Externí odkaz:
https://doaj.org/article/ad25d721f4b0427089cf47b40c777dee
Autor:
Elisa Baldelli, Mahalakshmi Subramanian, Abduljalil M. Alsubaie, Guy Oldaker, Maria Emelianenko, Emna El Gazzah, Sara Baglivo, Kimberley A. Hodge, Fortunato Bianconi, Vienna Ludovini, Lucio Crino’, Emanuel F. Petricoin, Mariaelena Pierobon
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 6, p 2819 (2021)
Targetable alterations in cancer offer novel opportunities to the drug discovery process. However, pre-clinical testing often requires solubilization of these drugs in cosolvents like dimethyl sulfoxide (DMSO). Using a panel of cell lines commonly us
Externí odkaz:
https://doaj.org/article/4662241e81ab4ae4b6c2aac8cda44a2d
Autor:
Annamaria Siggillino, Paola Ulivi, Luigi Pasini, Maria Sole Reda, Elisa Chiadini, Francesca Romana Tofanetti, Sara Baglivo, Giulio Metro, Lucio Crinó, Angelo Delmonte, Vincenzo Minotti, Fausto Roila, Vienna Ludovini
Publikováno v:
Diagnostics, Vol 10, Iss 12, p 1062 (2020)
Analysis of circulating cell-free tumor DNA (cftDNA) has emerged as a specific and sensitive blood-based approach to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients. Still, there is some debate
Externí odkaz:
https://doaj.org/article/fd3f3ec7ec2447269d94d487d5b4507b
Autor:
Sara Baglivo, Martina Mandarano, Guido Bellezza, Vincenzo Minotti, Angelo Bonaiti, Matthias J. Fischer, Ilaria Birocchi, Fausto Roila, Niccolò Metelli, Vienna Ludovini, Giulio Metro
Publikováno v:
Oncology and Therapy. 10:291-300
Treatment with immune checkpoint inhibitors (ICIs) that target the programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) axis is usually ineffective in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cel
Autor:
Giulio Metro, Sara Baglivo, Niccolò Metelli, Angelo Bonaiti, Roberta Matocci, Bruna Di Girolamo, Martina Mandarano, Claudia Colafigli, Guido Bellezza, Fausto Roila, Vienna Ludovini
Publikováno v:
Journal of chemotherapy (Florence, Italy).
Lorlatinib is an active treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) pretreated with ALK-tyrosine kinase inhibitors (-TKIs). However, there is paucity of data on the activity of platinum/pemetrex